Michael G

ViewRay, Inc.

At ViewRay, our vision is clear: conquer cancer by re-envisioning radiation therapy., giving doctors new and better ways to treat their patients. ViewRay®, Inc. (NASDAQ:VRAY) shifts the paradigm in cancer treatment with the MRIdian® MRI-guided adaptive radiotherapy system. We're changing radiation therapy for the better with accurate, precise and personalized cancer treatment that no other system delivers, addressing the key limitations of existing external-beam radiation therapy technologies. Real-time imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian shapes the dose to fit the day. It's the only MR solution that enables fully integrated adaptive treatment with complete, on-table re-optimization of the daily treatment plan. It knows when to strike – and when to stop. MRIdian is the only RT solution with automated beam gating for precise and accurate dosing. When the tumor moves, the beam stops. The result? Better outcomes for patients. After seven years of clinical use, MRIdian has treated more than 12,500 patients worldwide. We're an innovative, entrepreneurial company with big ambitions, unlimited potential and a passion for a culture that is diverse and committed to our physicians and their patients. If you're ready to change the way the world views cancer, come join our team.